CONFIRM试验早期结果:PSMA PET/CT在前列腺癌主动监测中的应用
CONFIRM试验是一项前瞻性非随机交叉研究,纳入60例具有高危特征的低级别前列腺癌主动监测患者,评估PSMA PET/CT在确认活检前检测临床显著前列腺癌(csPC)的价值。结果显示73.3%患者存在PSMA avid病灶,其中61.4%为csPC,45.5%的病灶MRI未发现;PSMA PET/CT影响了20%的治疗决策,并为38.9%的患者继续主动监测提供信心。
要点
- PSMA PET/CT在主动监测患者中可检测到73.3%的PSMA avid病灶,其中61.4%为csPC。
- 45.5%的PSMA avid病灶为MRI隐匿,提示PSMA PET/CT可补充MRI不足。
- PSMA PET/CT影响20%的治疗决策,并为38.9%患者继续主动监测提供信心。
核心结论
- PSMA PET/CT有望通过识别csPC和MRI隐匿病灶来改善主动监测中的风险分层。
研究设计与样本
- 前瞻性、非随机、交叉临床试验(ANZCTR ID ACTRN12621001648819)的初步分析,纳入60例具有高危特征的低级别前列腺癌主动监测患者。
主要发现
- 44例(73.3%)患者存在PSMA avid病灶,其中27例(61.4%)为csPC(GG≥2)。
- 20个(45.5%)PSMA avid病灶为MRI隐匿。
- 24例(40%)患者在多学科会议中被建议积极治疗,其中12例(20%)的决策受PSMA PET/CT影响。
- PSMA PET/CT通过排除PSMA avid病灶(14例,38.9%)和多灶性疾病(4例,11.1%)为继续主动监测提供信心。
关键数值与推荐
- 高危特征定义为:GG1且PSA>10 ng/ml或PSA密度>0.15 ng/ml/ml;高体积GG1;GG1伴MRI PI-RADS 4或5病灶;或低体积GG2前列腺癌。
- 患者在诊断后3-6个月接受多参数MRI和[18F]标记的PSMA PET/CT,诊断后6-9个月接受确认活检。
临床怎么用
- PSMA PET/CT可作为主动监测中确认活检前的补充工具,帮助识别MRI隐匿的csPC并指导治疗决策。
局限性
- 样本量小且随访时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is growing evidence on the utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) for detection of clinically significant prostate cancer (csPC), but there are limited data on its use in active surveillance (AS). The CONFIRM trial aims to determine the utility of PSMA PET/CT in detecting csPC before confirmatory biopsy during AS. METHODS: This is an initial analysis of a prospective, nonrandomised, crossover clinical trial (ANZCTR ID ACTRN12621001648819) that included men on AS for newly diagnosed low-grade prostate cancer (PC) with "high-risk" features. High risk was defined as grade group (GG) 1 disease with elevated prostate-specific antigen (PSA; >10 ng/ml, or PSA density >0.15 ng/ml/ml), high-volume GG 1, GG 1 with Prostate Imaging-Reporting and Data System 4 or 5 lesion on magnetic resonance imaging (MRI), or low-volume GG 2 PC. Patients underwent multiparametric MRI and [18F]-labelled radioligand PSMA PET/CT 3-6 mo after diagnosis, and confirmatory biopsy 6-9 mo after diagnosis. KEY FINDINGS AND LIMITATIONS: Between November 2021 and September 2023, 60 patients (median age 62.5 yr) were enrolled. PSMA-avid lesions were identified in 44 patients (73.3%), of whom 27 (61.4%) harboured csPC (GG ≥2). Of the PSMA-avid lesions, 20 (45.5%) were MRI-occult. At a subsequent multidisciplinary meeting, active treatment was recommended for 24 patients (40%), with PSMA PET/CT findings influencing 12 (20%) of the decisions. PSMA PET/CT provided reassurance regarding the decision to continue AS by excluding PSMA-avid lesions in 14 cases (38.9%) and multifocal disease in four (11.1%). Our findings are limited by the small sample size and short follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: PSMA PET/CT appears to hold promise for improving risk stratification during AS by identifying csPC and MRI-occult lesions.
引用
- Liu J, Harewood L, Bagguley D, et al. Early Results from the CONFIRM Trial: Utility of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40335400. doi:10.1016/j.euo.2025.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。